Navigation Links
Leading Researchers in Vision Impairment and Blindness to Present at EURETINA Winter Meeting
Date:2/1/2013

in the coming year on the ideal level of transcorneal electrical stimulation for patients with RP and its long-term effects, leaders in vision impairment are becoming increasingly eager to learn more about the potential benefits of the new therapy for earlier stage RP patients."

For more information on the Retina Implant and Okuvision presentations at EURETINA's Winter Meeting in Rome, please visit the conference Website.

About Retinitis Pigmentosa
Retinitis pigmentosa (RP) is one of the most common forms of inherited retinal degenerations affecting 1 in every 3,000-4,000 people in Europe. A progressive condition that gets worse over time, RP typically causes severe vision problems in adulthood. Retinal implants represent tremendous promise for enabling RP patients to regain sight.

About Retina Implant AG
Retina Implant AG is the leading developer of subretinal implants for partially sighted and blind patients. After extensive research with German university hospitals and institutes which began with a large grant from the German Federal Ministry of Research and Education in 1996, Retina Implant AG was founded by Dr. Eberhart Zrenner and his colleagues in 2003 with private investors with the goal of developing a fully-functioning electronic retinal implant to restore useful vision to the blind. Retina Implant began implanting in human patients in 2005 and started a second clinical trial in 2010. To learn more, visit: http://www.retinaimplant.de/.

About Okuvision GmbH
Founded by the leaders of Retina Implant AG in 2007, Okuvision GmbH is an innovator in the field of transcorneal electrical stimulation (TES) for patients with early and intermediate stage retinitis pigmentosa. Building on the lessons learned through the use of Retina
'/>"/>

SOURCE Retina Implant AG
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Leading Cardiologist Dispels the Myths about Dietary Supplement Niacin
2. DenMat Announces Signing a Purchase Agreement to Acquire PeriOptix Inc., Leading Provider of Magnification and Illumination Technologies
3. Drugs.com Releases Q3 Sales for Top 100 U.S. Drugs: Singulair Drops But Nexium and Abilify Remain the Leading Brands
4. World Diagnostic Imaging Market Outlook and Leading Suppliers Business Strategies and Marketing Tactics
5. Validus Pharmaceuticals Now Exclusively Marketing Six Established U.S. Product Lines Purchased From Leading Healthcare Company
6. Optimal Radiology Partners with Leading Radiology Practice
7. Frost & Sullivan Solidifies the Prominence of Leading Organizations through Best Practice Recognition
8. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
9. 90 Presentations at Leading Radiation Oncology Meeting Demonstrate the Breadth and Depth of Clinical Evidence for Accuray Technologies
10. LABSCO Implements Leading-Edge Technology to Support Growth and Seize Opportunities in the Clinical Laboratory Market
11. Presentations at Leading Radiation Oncology Meeting Highlight CyberKnife Prostate Outcomes from Patients at More Than 40 Centers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... MENLO PARK, Calif. , May 29, ... (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical ... therapies in new orphan drug indications, presented additional ... Cancer Research (AACR) Advances in Brain Cancer Research ... product candidate VAL-083 (dianhydrogalactitol) to treat ...
(Date:5/29/2015)... -- World-renowned prostate surgeon and New York Urologist, Dr. David ... MR/Ultrasound Fusion-Guided Biopsy for detecting aggressive prostate cancer ... at Lenox Hill Hospital is the only center using the ... York City . We,ve seen tremendous improvement in detecting ... of an MRI makes for a much more accurate diagnosis, ...
(Date:5/28/2015)... HOUSTON , May 28, 2015 /PRNewswire/ - ESSA Pharma ... results for the second quarter and three and six months ... in Canadian dollars and in accordance with International Financial Reporting ... ESSA recorded a net loss of $5.9 million ($0.35 per ... (Q2-2015), compared to a net loss of $0.4 million ($0.03 ...
Breaking Medicine Technology:DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 2Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 3Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 4Essa Pharma Inc. Reports Second Quarter 2015 Financial Results 5
... 9 Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... with eight presentations (including three oral talks and two ... Scientific Sessions in New Orleans by Isis and its ... ISIS-SGLT2Rx showing a robust and sustained reduction in sodium ...
... for America,s Health (TFAH) and the Robert Wood Johnson ... which finds that Americans rank prevention as the most ... funding for prevention programs to reduce disease and keep ... conducted by Greenberg Quinlan Rosner Research and Public Opinion ...
Cached Medicine Technology:Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions 2Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions 3Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions 4Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions 5Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity at ADA Scientific Sessions 6New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform 2New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform 3New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform 4New Poll Finds Disease Prevention is Top Priority for Americans in Health Reform 5
(Date:5/29/2015)... Johnson & Johnson and its ... lawsuit ( http://www.risperdallawsuit2014.com/ ) settlement with a California ... use of the antipsychotic medication. According to court ... third bellwether trial to involve male breast growth ... Pennsylvania’s Philadelphia Court of Common Pleas, where more ...
(Date:5/29/2015)... May 29, 2015 A group of doctors ... joined the national effort to teach this “new math” to ... U.S. have been “sickened” by the recent implementation of Common ... or hate it, Common Core is now a reality in ... Parents are now seeking ways to improve common core ...
(Date:5/29/2015)... FL (PRWEB) May 29, 2015 ... Utah, recently partnered with Stratus Video ... which will facilitate better communication and timely ... (LEP) and hearing loss. Stratus’ video remote ... in-house translators, enabling staff to quickly access ...
(Date:5/29/2015)... 29, 2015 The print component of ... circulation of approximately 250,000 and an estimated readership of ... vast social media strategy, and across a network of ... digital version of the campaign, click here. ... publication. Inside, the actress, model and producer details her ...
(Date:5/29/2015)... New York, NY (PRWEB) May 29, 2015 ... readers on the “beauty of protection”. Skin Health ... through USA Today within the markets of New York, ... reach an estimated 750,000 readers. Its digital counterpart will ... online content hubs. To read more the Skin Health ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 2Health News:Risperdal Lawsuit Selected as Pennsylvania’s Third Bellwether Gynecomastia Case Settles Hours Before Trial 3Health News:Doctors Discover a Cure for the Common Core 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 2Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 3Health News:Stratus Video Interpreting Partners With Intermountain Healthcare to Provide On-Demand Interpretation Services for Patients With Limited English Proficiency (LEP) 4Health News:Mediaplanet Launches “Skin Health” Campaign Featuring Colorescience 2
... FASgen is pleased to report the,publication of ... one of the Company,s proprietary compounds. In a ... supported,research into the selective inhibition of fatty acid ... potential therapeutic agent against various,forms of solid tumor ...
... KAYSVILLE, Utah, Dec. 28 A Utah company wants ... Virtual Trainer Pro.,MediaRif,s online software takes the complexity out ... Strength training is on the rise, and not just ... reports that 21.9% of women use,strength training as a ...
... KV,s Securities until February 15, ... ... KV Pharmaceutical Company,(NYSE: KVa/KVb) a fully integrated specialty pharmaceutical company ... products,announced today that NYSE Regulation, Inc. has granted KV,s request for ...
... 28 Caraco Pharmaceutical,Laboratories, Ltd., (Amex: CPD ) ... has granted final approval for the Company,s,Abbreviated New Drug ... 5 mg and 10 mg, (Cetirizine HCl)., Cetirizine ... products in,two strengths of 5 mg and 10 mg, ...
... Therapeutics Inc.,("Transition" or the "Company") (TSX: TTH; NASDAQ: ... has been appointed Vice President of,Business Development. Since ... key member of the Company,s management team and ... a broad range of activities,including licensing and intellectual ...
... that contact with some commonly used pesticides in farm work ... women are an understudied occupational group, said Jane Hoppin, Sc.D., ... author of the study. More than half the women in ... about the risks. , The study was published in the ...
Cached Medicine News:Health News:Personal Fitness Training Goes Online for 2008 2Health News:KV Pharmaceutical Company Announces NYSE Listing Extension 2Health News:KV Pharmaceutical Company Announces NYSE Listing Extension 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R) 2Health News:Transition Therapeutics Announces Appointment of Vice-President of Business Development 2Health News:Handling pesticides associated with greater asthma risk in farm women 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: